IP Library Granted Patent US 8,461,105
Granted Patent B2
US 8,461,105 · App. 12/585,574 · Granted Jun 11, 2013

Polymer-based sustained release device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,461,105
App. No.
12/585,574
Granted
Jun 11, 2013
Kind
B2
Abstract

This invention relates to compositions for the sustained release of biologically active polypeptides, and methods of forming and using said compositions, for the sustained release of biologically active polypeptides. The sustained release compositions of this invention comprise a biocompatible polymer having dispersed therein, a biologically active polypeptide and a sugar.

Claims (7)

1. An injectable composition for sustained release of a glucoregulatory polypeptide, comprising:

a biocompatible polymer having the glucoregulatory polypeptide dispersed therein so as to be present at about 0.5 to 5% (w/w) of the weight of the composition, and a sugar dispersed therein so as to be present at about 0.1 to 5% (w/w) of the weight of the composition,

wherein the injectable composition is free from additional ingredients that alter the rate of release of the glucoregulatory polypeptide from the injectable composition.

2. The injectable composition of claim 1 , wherein the composition has a release profile in which the C max of the glucoregulatory peptide occurs between day 21 and day 28.

3. A method of treating a patient suffering from Type 2 diabetes, comprising administering a therapeutically effective amount of the injectable composition of claim 1 .

4. A method of treating a patient suffering from a condition selected from the group consisting of Type 2 diabetes, impaired glucose tolerance, obesity, and cardiovascular disorder, the method comprising administering a therapeutically effective amount of the injectable composition of claim 1 .

5. The method of claim 4 , wherein the composition has a release profile in which the C max of the glucoregulatory peptide occurs between day 21 and day 28.

Assignments (10)
SECURITY INTEREST Recorded Feb 13, 2026
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 074858/0405 →
RELEASE OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (073213/0302) Recorded Feb 13, 2026
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 074858/0429 →
SECURITY INTEREST Recorded Oct 23, 2025
From: ALKERMES PHARMA IRELAND LIMITED
To: JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT
Reel/Frame 073213/0302 →
RELEASE OF PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Dec 24, 2024
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 069771/0548 →
RELEASE BY SECURED PARTY (SECOND LIEN) Recorded Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
MERGER Recorded Aug 2, 2012
From: ALKERMES CONTROLLED THERAPEUTICS, INC. II
To: ALKERMES, INC.
Reel/Frame 028712/0300 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2012
From: WRIGHT, STEVEN G.; CHRISTENSEN, TROY; YEOH, THEAN Y.; RICKEY, MICHAEL E.; HOTZ, JOYCE M.; KUMAR, RAJESH; COSTANTINO, HENRY R.
To: ALKERMES CONTROLLED THERAPEUTICS, INC. II
Reel/Frame 028712/0257 →
CONFIRMATORY ASSIGNMENT Recorded Dec 15, 2011
From: ALKERMES, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 027396/0409 →
PATENT SECURITY AGREEMENT (FIRST LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
PATENT SECURITY AGREEMENT (SECOND LIEN) Recorded Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →